Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
about
Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastomaProtein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2The ubiquitin proteasome system in neuropathologyLoss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpointMaintaining Genome Stability in Defiance of Mitotic DNA DamageAurora Kinase Inhibitors: Current Status and OutlookPhenotypic Screening Approaches to Develop Aurora Kinase Inhibitors: Drug Discovery PerspectivesAurora kinase A in gastrointestinal cancers: time to targetTACC3 Is Important for Correct Progression of Meiosis in Bovine OocytesA Cell Biologist's Field Guide to Aurora Kinase InhibitorsAurora-A-Dependent Control of TACC3 Influences the Rate of Mitotic Spindle AssemblyPhosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability.Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell linesCrystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug designDevelopment of o -Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase InhibitorsCrystal Structure of Human Aurora B in Complex with INCENP and VX-680Optimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaSelective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity ScreenAurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubulesAurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells.NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumorsQuantitative phosphoproteomics reveals new roles for the protein phosphatase PP6 in mitotic cellsBPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cellsNon ionising radiation as a non chemical strategy in regenerative medicine: Ca(2+)-ICR "In Vitro" effect on neuronal differentiation and tumorigenicity modulation in NT2 cellsInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsAurora kinase-A deficiency during skin development impairs cell division and stratificationAurora A is essential for early embryonic development and tumor suppressionIdentification of Aurora-A Inhibitors by Ligand and Structure-Based Virtual Screening.Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization.Aurora B spatially regulates EB3 phosphorylation to coordinate daughter cell adhesion with cytokinesis.Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells.Elevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells.A current review of targeted therapeutics for ovarian cancer.Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells.Aurora kinase inhibitors--rising stars in cancer therapeutics?In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitorsA phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.Quantitative proteomics combined with BAC TransgeneOmics reveals in vivo protein interactions
P2860
Q24296639-B3713BD5-B726-4ABD-A1CD-88C55EA13DBAQ24321572-2C1E4F7C-B206-4327-8750-CE1A5CD2483CQ24644208-DE7EFB21-A313-495F-86B2-92049CCA0A42Q24652321-A32CE369-65AD-40CA-BF24-02536204BAABQ26738970-F86CF177-C384-4B4F-93C1-DD083733919AQ26770583-02BE9213-DEA7-4FD0-8F1F-3053042366AAQ26771369-7DCCDA58-5E5B-49AF-835F-1DD7AD1A37B8Q26864277-CBDBE12C-39F0-4286-B726-6C72C34364C5Q27302875-FC95B0F5-D74B-4EA7-AA85-FDFD5297FC3CQ27308125-D341ABAD-57F9-49A8-A484-38C76A42C443Q27310808-69A6E7B9-C31B-4640-94A0-E3EC18AA2EF6Q27321639-F317BC3C-E093-4454-BA5D-5B4872590D47Q27334288-8556D347-4CB5-41AC-8033-7792FAA3E441Q27658934-4E941CC8-D0CD-445D-9460-0B9D9779A3D5Q27670770-19B7D15B-15DE-4E7D-AE96-08DEACA2E5A4Q27671676-7F17399E-F154-42BB-A5BD-4CE88AC86E2BQ27674324-7D417E6E-5BF9-4004-B36D-2104EC28E82CQ27674986-7E8ECEAD-40D1-4F6A-89C5-57205C71684FQ27677506-52CA037F-2134-44E5-9917-842038CC86C5Q27680538-70C2FC3B-1194-4452-87E6-C70EBD0B0B57Q28287972-D93D5F0A-BD73-4AF7-9E34-BAF3166BED07Q28468277-F1082C41-2314-434E-BB76-860797718FB7Q28476664-4591249C-F6FE-453C-AB6F-377DAA1BC34FQ28486085-2FF68C21-D603-4C31-B044-089CD036D363Q28545195-72F7A5FB-83B7-4409-A1D1-0BE82FD2D35AQ28590357-54284940-D2A6-4B6B-BCFC-8C72D7B84BE3Q28590685-E441E636-9F15-4B6D-A6EB-399DBA3597A8Q30009428-6D14DBE3-24BE-41E9-A8DF-2E99ED310EDDQ30252352-8EA2AA13-2D5E-41AF-BBC1-5D3FCE8E3246Q30479689-B71D4978-564C-4ED0-9427-C7355FC64455Q30495553-065FC26F-0AEC-44A2-BA2F-5E8C4EC5F171Q30540082-3D5AEB77-0D97-4B0F-A53B-6F1462A2D04FQ30637438-8B0C1DA2-B371-4C14-B632-F25F83E67F90Q33523638-C8B819FD-EECA-4058-B68B-C1DABC0C214CQ33580998-E92AD806-909F-4145-97B6-AD3D407517F7Q33611307-C7139AD6-B3D1-4501-B9EC-5A77478D0056Q33647643-0E067C7B-E9D1-4473-BB8B-AA79CA3EF54CQ33648377-5DC7BD96-7897-48A5-8E8A-17065171ADF0Q33676809-D5971879-3102-4E71-BFF4-72BC8E6EC165Q33861783-65C21CD2-3CEB-4D3F-BFF5-5EBD040353F9
P2860
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antitumor activity of MLN8054, ...... e inhibitor of Aurora A kinase
@ast
Antitumor activity of MLN8054, ...... e inhibitor of Aurora A kinase
@en
type
label
Antitumor activity of MLN8054, ...... e inhibitor of Aurora A kinase
@ast
Antitumor activity of MLN8054, ...... e inhibitor of Aurora A kinase
@en
prefLabel
Antitumor activity of MLN8054, ...... e inhibitor of Aurora A kinase
@ast
Antitumor activity of MLN8054, ...... e inhibitor of Aurora A kinase
@en
P2093
P2860
P356
P1476
Antitumor activity of MLN8054, ...... e inhibitor of Aurora A kinase
@en
P2093
Bradley Stringer
Christopher F Claiborne
Deborah R Wysong
Emily T Ray
Gabriel S Weatherhead
Jeffrey A Ecsedy
Jessica J Huck
Joseph B Bolen
Kara M Hoar
Katherine M Galvin
P2860
P304
P356
10.1073/PNAS.0608798104
P407
P577
2007-02-23T00:00:00Z